Change of Safety Interval from Hyperviscosity Problem in COVID-19 Vaccine Recipient with Underlying Diabetic Problem

Detalles Bibliográficos
Autores principales: Sookaromdee, Pathum, Wiwanitkit, Viroj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547390/
https://www.ncbi.nlm.nih.gov/pubmed/34760686
http://dx.doi.org/10.4103/ijem.ijem_308_21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547390/
https://www.ncbi.nlm.nih.gov/pubmed/34760686
http://dx.doi.org/10.4103/ijem.ijem_308_21

Ejemplares similares